Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683191 | 0.82 | TSHR (0.57) | TSHRALDH1A1TDP1CYP3A4MEN1 | |
| SCHEMBL10880389 | 0.80 | GPR35 (0.54) | TSHRGPR35ALDH1A1TDP1CYP3A4 | |
| SCHEMBL2056814 | 0.80 | TSHR (0.60) | TSHRALDH1A1TDP1CYP3A4MEN1 | |
| SCHEMBL3280548 | 0.80 | GPR35 (0.54) | TSHRGPR35ALDH1A1TDP1CYP3A4 | |
| SCHEMBL1369143 | 0.80 | GPR35 (0.54) | TSHRGPR35ALDH1A1TDP1CYP3A4 | |
| SCHEMBL1635417 | 0.78 | TSHR (0.53) | TSHRALDH1A1TDP1CYP3A4MEN1 | |
| SCHEMBL30857795 | 0.78 | TSHR (0.53) | TSHRALDH1A1TDP1CYP3A4MEN1 | |
| SCHEMBL28065463 | 0.78 | TSHR (0.53) | TSHRGPR35ALDH1A1TDP1CYP3A4 | |
| Hydrochloric Acid SCHEMBL28240513 | 0.78 | GPR35 (0.52) | TSHRGPR35ALDH1A1TDP1CYP3A4 | |
| SCHEMBL38652666 | 0.77 | TDP1 (0.52) | TSHRGPR35ALDH1A1TDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390923-B2 | Propionamide derivatives useful as androgen receptor modulators | ORION CORPORATION (FI) | 2008-06-24 | — | — | US | disclosed |
| US-20070123512-A1 | Propionamide derivatives useful as androgen receptor modulators | ORION CORPORATION (FI) | 2007-05-31 | — | — | US | disclosed |
| EP-1641745-A1 | PROPIONAMIDE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | Orion Corporation (FI) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005000794-A1 | PROPIONAMIDE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | ORION CORPORATION (FI) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123512-A1 | Propionamide derivatives useful as androgen receptor modulators | NR5A1, FSHR, GNRHR | TSHR 70/4885GPR35 47/4885ALDH1A1 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.